Published in Exp Cell Res on March 01, 1985
Transcriptional repression of human cad gene by hypoxia inducible factor-1alpha. Nucleic Acids Res (2005) 1.35
Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin. Leuk Res (2011) 1.00
Regulation of cell proliferation under extreme and moderate hypoxia: the role of pyrimidine (deoxy)nucleotides. Br J Cancer (1994) 0.82
Mechanism and control of degradation and resynthesis of adenylates in tumour cells. Biochem J (1991) 0.79
Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia (2006) 2.88
Horizontal gene transfer promoted evolution of the ability to propagate under anaerobic conditions in yeasts. Mol Genet Genomics (2004) 1.32
GRC5 and NMD3 function in translational control of gene expression and interact genetically. Curr Genet (1999) 1.25
Prevention of high-fat diet-induced adipose tissue remodeling in obese diabetic mice by n-3 polyunsaturated fatty acids. Int J Obes (Lond) (2006) 1.22
Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. Eur J Biochem (1996) 1.06
Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J (1999) 1.03
Requirements for the mitochondrial import and localization of dihydroorotate dehydrogenase. Eur J Biochem (2000) 1.01
Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact (2000) 0.99
Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem Pharmacol (1998) 0.96
p53-induced apoptosis in the human T-ALL cell line CCRF-CEM. Oncogene (1997) 0.95
Expression, purification, and characterization of histidine-tagged rat and human flavoenzyme dihydroorotate dehydrogenase. Protein Expr Purif (1998) 0.91
Complementary therapy use in patients with glioma: an observational study. Neurology (2010) 0.91
Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects? Eur J Biochem (2001) 0.89
Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.88
The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes Immun (2007) 0.87
Restimulation of cell cycle progression by hypoxic tumour cells with deoxynucleosides requires ppm oxygen tension. Exp Cell Res (1987) 0.87
Mesenchymal stem cells in cartilage repair: state of the art and methods to monitor cell growth, differentiation and cartilage regeneration. Curr Med Chem (2010) 0.86
Detection and location of the enzymes of de novo pyrimidine biosynthesis in mammalian spermatozoa. Reproduction (2002) 0.86
Uridine, but not cytidine can sustain growth of Ehrlich ascites tumor cells in glucose-deprived medium with altered proliferation kinetics. Eur J Cell Biol (1985) 0.86
Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis. Oncogene (1999) 0.85
Enteral nutrition is associated with improved outcome in patients with severe sepsis. A secondary analysis of the VISEP trial. Med Klin Intensivmed Notfmed (2013) 0.85
Anti-peptide immunoglobulins from rabbit and chicken eggs recognise recombinant human dihydroorotate dehydrogenase and a 44-kDa protein from rat liver mitochondria. Eur J Biochem (1996) 0.84
L-arginine stimulates NO-dependent vasodilation in healthy humans--effect of somatostatin pretreatment. J Investig Med (1999) 0.84
In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis. Transplant Proc (1997) 0.84
Characterization of the deoxynucleoside-dependent reversal of hypoxia-induced inhibition of cell cycle progression in Ehrlich ascites tumor cells. Eur J Cell Biol (1985) 0.83
Localization of dihydroorotate oxidase in myocardium and kidney cortex of the rat. An electron microscopic study using the cerium technique. Histochem Cell Biol (1995) 0.83
Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria. Biochem Pharmacol (1998) 0.83
Regulation of cell proliferation under extreme and moderate hypoxia: the role of pyrimidine (deoxy)nucleotides. Br J Cancer (1994) 0.82
Effects of gabapentin and pregabalin on K+-evoked 3H-GABA and 3H-glutamate release from human neocortical synaptosomes. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.82
Redoxal as a new lead structure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism. FEBS Lett (2000) 0.82
Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Med Oncol Tumor Pharmacother (1989) 0.81
Indirect inhibition of mitochondrial dihydroorotate dehydrogenase activity by nitric oxide. Free Radic Biol Med (2000) 0.80
Partial agonism at the human alpha(2A)-autoreceptor: role of binding duration. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.80
Molecular cloning and sequence analyses of rat liver dihydroorotate dehydrogenase. Adv Exp Med Biol (1994) 0.80
Deoxycytidylate shortage is a cause of G1 arrest of ascites tumor cells under oxygen deficiency. FEBS Lett (1983) 0.80
Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro. Biochem Pharmacol (1992) 0.79
Role of endogenous nitric oxide in circadian blood pressure regulation in healthy humans and in patients with hypertension or atherosclerosis. J Investig Med (2000) 0.79
On the role of dihydroorotate dehydrogenase in growth cessation of Ehrlich ascites tumor cells cultured under oxygen deficiency. Eur J Biochem (1980) 0.79
Interaction between dexamethasone and butyrate in apoptosis induction: non-additive in thymocytes and synergistic in a T cell-derived leukemia cell line. Cell Death Differ (1999) 0.78
Rat dihydroorotate dehydrogenase: isolation of the recombinant enzyme from mitochondria of insect cells. Protein Expr Purif (1997) 0.78
Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany? Ann Oncol (2010) 0.78
Energy parameters, macromolecular synthesis and cell cycle progression of in vitro grown Ehrlich ascites tumor cells after inhibition of oxidative ATP synthesis by oligomycin. Z Naturforsch C (1983) 0.78
HLö 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases. Arch Toxicol (1992) 0.77
Evidence from in vitro studies that dihydroorotate dehydrogenase may be a source of toxic oxygen species. Adv Exp Med Biol (1991) 0.77
Anaerobiosis and oxygen recovery: changes in cell cycle distribution of Ehrlich ascites tumor cells grown in vitro. Virchows Arch B Cell Pathol (1978) 0.77
Lipogenesis in Ehrlich ascites tumor cells under anaerobic culture conditions. J Cancer Res Clin Oncol (1979) 0.76
Immunocytochemical detection of mitochondrial dihydroorotate dehydrogenase in human spermatozoa. Int J Androl (2000) 0.76
Rapamycin-induced impaired wound healing is associated with compromised tissue lactate accumulation and extracellular matrix remodeling. Eur Surg Res (2011) 0.76
The bispyridinium-dioxime HLö-7. A potent reactivator for acetylcholinesterase inhibited by the stereoisomers of tabun and soman. Biochem Pharmacol (1989) 0.76
[Diagnosis of vesico-intestinal fistulas by contrast medium enhanced 3-D ultrasound]. Ultraschall Med (2001) 0.75
Cell proliferation and metabolism of Ehrlich ascites tumor cells grown in chemically defined albumin medium for several passages. Z Naturforsch C (1980) 0.75
[Radiotherapeutic quality assurance in the Hodgkin's disease study HD4 supported by the BMFT (Bundesministerium für Forschung und Technologie)]. Strahlenther Onkol (1990) 0.75
The effect of SH-blocking agents on the p-nitrophenylphosphatase activity of intact Ehrlich ascites tumor cells. FEBS Lett (1975) 0.75
Lipid metabolism of Ehrlich ascites tumor cells grown in chemically defined albumin medium. Z Naturforsch C (1980) 0.75
Proceedings: On the number, reactivity and function of SH groups at the surface of Ehrlich ascites tumor cells. Hoppe Seylers Z Physiol Chem (1974) 0.75
[Enrolment of intensive care patients in clinical studies. Ethical, legal and organizational problems from an interdisciplinary point of view]. Med Klin Intensivmed Notfmed (2012) 0.75
[Studies of the number, reactivity and function of SH groups on the surface of Ehrlich ascites tumor cells]. Acta Histochem Suppl (1976) 0.75
[Intermediate results of therapy studies HD1, HD2 and HD3 of the German Hodgkin Study Group]. Med Klin (Munich) (1986) 0.75
[Determination of prosocial attitudes of mothers for the evaluation of familial socialization for brain-damaged children]. Arztl Jugendkd (1985) 0.75
Increased level of histone H1(0) messenger RNA in hypoxic Ehrlich ascites tumor cells. Exp Cell Res (1990) 0.75
[Diagnosis of the intelligence structure and ability to concentrate of children with and without brain dysfunction using Horn's achievement test]. Arztl Jugendkd (1984) 0.75
[Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group]. Med Klin (Munich) (1992) 0.75
Further investigations on the p-nitrophenylphosphatase activity of intact Ehrlich ascites tumor cells. Z Naturforsch C (1978) 0.75
Influence of bromoacetylsulfanilic acid and and bromoacetylaminoisophthalic acid on sulfhydryl groups of Ehrlich ascites tumor cells. FEBS Lett (1976) 0.75
[Clinically relevant prognostic factors in malignant lymphoma]. Internist (Berl) (1993) 0.75
[Aspects of family-oriented diagnosis in compulsory legal family expert assessment]. Psychiatr Neurol Med Psychol (Leipz) (1990) 0.75
[Therapy of Hodgkin's lymphomas. Results of the German Hodgkin's Disease Study Group]. Onkologie (1988) 0.75
Cytokinetic studies on the switch from glucose to uridine metabolism, and vice versa, of Ehrlich ascites tumour cells in vitro. Cell Tissue Kinet (1987) 0.75
Proliferation and metabolic activities of Ehrlich ascites tumor cells in chemically defined albumin media. Z Naturforsch C (1980) 0.75
[Methods of controlled clinical studies]. Internist (Berl) (1998) 0.75
[Therapy of Hodgkin's disease. Optimization over 4 study generations]. Internist (Berl) (1998) 0.75
[Characteristics of the personality structure of children with minimal brain damage--a study of 12-year-olds using a multidimensional personality test (HSPQ)]. Arztl Jugendkd (1985) 0.75
[Therapy studies of the German Hodgkin's Study Group. Intermediate results of the study protocols HD1, HD2, and HD3]. Onkologie (1987) 0.75
Simultaneous analysis of mitochondrial activity and DNA content in Ehrlich ascites tumor cells by dual parameter flow cytometry. Histochemistry (1989) 0.75
[Quality standards and their assurance for study centers in the competence network malignant lymphoma]. Klin Padiatr (2003) 0.75
Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease. Leuk Lymphoma (1994) 0.75
[Participation in multicenter studies as quality control in the therapy of Hodgkin disease: an interim report]. Schweiz Med Wochenschr (1995) 0.75
The Second International Symposium on Hodgkin's Disease. Workshop III: Recommendations for future clinical trials. Ann Oncol (1992) 0.75
The effect of glucosone on the proliferation and energy metabolism of in vitro grown Ehrlich ascites tumor cells. Z Naturforsch C (1981) 0.75
On the pH- and temperature dependence of the p-nitrophenylphosphatase activity of intact Ehrlich ascites tumor cells. FEBS Lett (1975) 0.75
Unexpectedly low incorporation of isotopic acetate into lipids of Ehrlich ascites tumor cells cultured in lipid-poor medium. Oncology (1979) 0.75
Cooperative trials of Hodgkin's lymphoma in the Federal Republic of Germany. J Cancer Res Clin Oncol (1990) 0.75